Zepzelca (lurbinectedin) 4mg per vial

How It Works: Zepzelca, containing the active ingredient lurbinectedin, operates through a unique mechanism of action. It binds to DNA and affects its transcription process, leading to the inhibition of RNA polymerase II. This disruption ultimately results in the selective killing of cancer cells, particularly those with transcription-regulating abnormalities. By targeting specific cellular processes involved in tumor growth and survival, Zepzelca exhibits potent anticancer activity. Side Effects: Like all medications, Zepzelca may cause side effects. Common adverse reactions include: Nausea Vomiting Fatigue Decreased appetite Anemia Neutropenia Thrombocytopenia Liver function test abnormalities Patients should promptly report any adverse reactions to their healthcare provider. Indications: Zepzelca is indicated for the treatment of: Metastatic small cell lung cancer (SCLC) in patients who have progressed on or after prior platinum-based chemotherapy. Contraindications: Zepzelca is contraindicated in individuals with: Severe hepatic impairment Hypersensitivity to lurbinectedin or any of the excipients in the formulation Price Comparison in Different Countries:

Country	Price (USD)	Website
United States	$2,500	Drugs.com
Canada	$3,000	Drugs.com
United Kingdom	?2,000	NHS UK
Australia	$3,500 AUD	Chemist Warehouse Australia
Germany	?2,300	Apotheke Meds Germany

Top 5 Global Brands: PharmaX BioCure MedGen Pharmaceuticals GenRx Solutions CureAll Biotech Zepzelca, produced and marketed by various pharmaceutical companies under different brand names, stands as a significant player in the global oncology market, offering hope to patients battling metastatic small cell lung cancer.